Izotropic stock analysis
Izotropic (IZOZF) Stock Price & Analysis
IZOZF Stock Chart & Stats
- Day’s Range
- $0.08 - $0.10
- 52-Week Range
- $0.07 - $0.30
- Previous Close
- $0.09
- Volume
- N/A
- Average Volume (3M)
- 38.80K
- Market Cap
- $6.14M
- Enterprise Value
- $20.58M
- Total Cash (Recent Filing)
- $57.78K
- Total Debt (Recent Filing)
- $3.21M
- Price to Earnings (P/E)
- ―
- Beta
- -0.46
- Next Earnings
- Dec 22, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Focused Breast-Imaging Product
A clearly defined product focus gives Izotropic a specific clinical use case and a basis for commercialization in breast imaging. If the system gains adoption, its dedicated design could support a differentiated position within diagnostic workflows and provide a foundation for future sales and service revenue.
Improved Loss Trajectory
The substantial reduction in net losses from 2022–2023 indicates progress in controlling expenses or reducing development costs, even though profitability remains negative. Sustaining this improvement would extend financial runway and reduce the operating scale required to reach breakeven after commercialization.
Lower Historical Cash Burn
Cash consumption is materially below the levels reported in 2022 and 2023, showing that operating outflows have been reduced during the development phase. Continued discipline could preserve resources for product commercialization, although the company still needs to eliminate its underlying cash deficit.
Bears Say
No Commercial Revenue
The absence of revenue means Izotropic has not yet demonstrated commercial demand or a functioning sales engine for IzoView. This leaves future performance dependent on successful product commercialization, customer adoption, and conversion of development work into recurring system and support revenue.
Negative Equity And Rising Debt
Persistent negative equity and increasing debt weaken financial flexibility and raise the likelihood that additional capital will be needed to sustain operations. Future financing or recapitalization could impose unfavorable terms or dilute existing holders, while debt adds obligations before the business generates revenue.
Persistent Cash Dependence
Negative operating and free cash flow across every reported period shows that the current business does not fund itself. Until revenue begins covering expenses and development needs, Izotropic must depend on outside capital, limiting strategic flexibility and increasing exposure to financing risk.
Izotropic News
IZOZF FAQ
What was Izotropic’s price range in the past 12 months?
What is Izotropic’s market cap?
When is Izotropic’s upcoming earnings report date?
How were Izotropic’s earnings last quarter?
Is Izotropic overvalued?
Does Izotropic pay dividends?
What is Izotropic’s EPS estimate?
How many shares outstanding does Izotropic have?
What happened to Izotropic’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Izotropic?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Izotropic
Izotropic Corporation operates as a MedTech enterprise, concentrating on the commercialization of diagnostic solutions for breast cancer. Their primary focus lies in developing and offering a breast CT imaging system alongside a 3D CT breast imaging platform, both specifically designed to enable earlier detection and more accurate diagnosis of the disease. Established in 2016, the company maintains its corporate base in Surrey, Canada.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Robert Louis Thast
- Employees
- 5
- Website
- izocorp.com
- Address
- 800 – 15355 24th Avenue, Surrey, BC, V4A 2H9, CA
Izotropic (IZOZF) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 6 | 11 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 4 | 0 | 8 |








